Home › NCT06787066

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

Who can join

Ages 18 to 70 · Women · Healthy volunteers welcome

Inclusion Criteria:

* Assigned female at birth
* 18-70 years of age
* Body mass index (BMI) \<30 kg/m2

Exclusion Criteria:

* Assigned male at birth
* Pregnancy, breastfeeding
* Body mass index ≥30 kg/m2
* Oral hormonal contraception in last 6 months, history of hormone replacement therapy, oophorectomy
* Current smoking/nicotine use
* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
* Nerve/neurologic disease
* Cardiovascular, hepatic, renal, respiratory disease
* Blood pressure ≥140/90 mmHg
* Diabetes, Polycystic ovarian syndrome
* Communication barriers
* Prescription medications

About the study

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

What is being tested

• Propranolol Hydrochloride (drug)
• Phentolamine Injection (drug)

Sponsor: University of Missouri-Columbia · Participants: 75 · Started: Jul 10, 2025

Contact the study team

• Jacqueline Limberg, PhD · Phone: 573-882-2420

Official record on ClinicalTrials.gov — NCT06787066

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.